Aktuellt
SENASTE
Redeye is encouraged by the news that the MIV-818 Phase Ib monotherapy trial is nearing completion. Medivir has included the last patient and will present top-line results at a scientific conference. While this is a slight delay compared to previously stated ambitions (top-line results in Q1, 2021), more importantly, Medivir reiterates the plan to start the next step, a combination trial, in H2, 2021. The company will communicate more details regarding study design in Q2.
LÄS MER
